Results
Max Biopharma Inc
08/04/2025 | Press release | Archived content
Oxy210 Reduces Senescence and Fibrosis in MASH Models
MAX BioPharma Reports on Oxy210's Inhibition of Hepatic Expression of Senescence-Associated, Pro-Fibrotic, and Pro-Inflammatory Genes in Mice During Development of MASH and in Hepatocytes In Vitro.
Max Biopharma Inc published this content on August 04, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 15, 2026 at 07:36 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]